PFE stock is trading at $26.58 — we rate it a Buy with a $29.29 average price target from 14 analysts. Goldman Sachs analyst Asad Haider summed up the consensus tension in a May note: “Q1 was clean, the obesity pipeline is real, but until 2028 approval data is in hand, this is a yield-and-pipeline-optionality story, not a growth story.” Our PFE stock price prediction 2026 reflects exactly that framing — a healthy 6.7% dividend yield, a Q1 EPS beat at $0.75, and a $10B Metsera acquisition that builds a credible second act behind a Covid franchise that has finally found its floor.
| Key Stock Data (PFE) | Value |
|---|---|
| Current Price | $26.58 |
| 52-Week Range | $24.48 – $32.10 |
| Market Cap | $151 billion |
| P/E Ratio (TTM) | 17.5 |
| EPS (Q1 2026, adj.) | $0.75 |
| Analyst Consensus | Buy |
| Average Price Target | $29.29 |
Key Takeaways
- Price & verdict: PFE stock price sits at $26.58 with a Buy rating — consensus $29.29 target implies 10.2% upside before the 6.7% dividend yield.
- Key stat: Q1 2026 adjusted EPS of $0.75 beat consensus; revenue of $14.5B grew 5% YoY against ongoing Covid franchise drag.
- Bull case: $10B Metsera acquisition gives Pfizer a credible obesity portfolio with 10 Phase III studies and first approval targeted for 2028.
- Bear case: Patent cliffs through 2028 (Eliquis, Ibrance) plus a 17.5 TTM P/E that already reflects a moderate recovery in pipeline contribution.
- Bottom line: Hold through volatility — the dividend pays you to wait for the obesity readouts, and the consensus PFE stock price prediction 2026 supports current entry levels.
Table of Contents
- Key Takeaways
- What Is Pfizer?
- Recent PFE Stock Performance
- PFE Valuation Analysis
- Bullish and Bearish Analyst Opinions on Pfizer
- PFE Stock Forecast 2026: Analyst Price Targets
- PFE Pipeline and Patent Cliff Roadmap
- How to Trade PFE via MEXC
- PFE Stock Forecast FAQs
What Is Pfizer?
Pfizer Inc. (NYSE: PFE) is one of the world’s largest biopharmaceutical companies, with $63.6B of FY2025 revenue spread across Oncology, Vaccines, Internal Medicine, Hospital, Inflammation & Immunology, and an emerging Obesity franchise. The portfolio includes Eliquis (anticoagulation, shared with BMY), Ibrance (breast cancer), Vyndaqel/Vyndamax (cardiomyopathy), Comirnaty (Covid vaccine, with BioNTech), and Paxlovid (Covid antiviral).
The strategic story for 2026 is twofold: (1) a managed decline of the Covid franchise as Comirnaty and Paxlovid revenue stabilises around a recurring vaccination-season cadence; and (2) the build-out of an obesity portfolio anchored by the $10B Metsera acquisition closed in November 2025. Investors comparing PFE to Eli Lilly stock price are looking at two very different points in the obesity cycle — Lilly is monetising Mounjaro and Zepbound today; Pfizer is two years from a first regulatory filing on its lead Metsera asset.
Recent PFE Stock Performance
PFE closed at $26.58 after a 5% rally on the back of the Q1 earnings beat. The 52-week range of $24.48 to $32.10 captures a stock that has spent most of 2026 grinding sideways while large-cap pharma peers like Merck stock price and Johnson & Johnson stock price have outperformed.
The Q1 print provided the first incremental positive catalyst since the Metsera deal announcement. Adjusted EPS of $0.75 cleared the $0.65 consensus, and revenue of $14.45B was modestly ahead of the $14.1B estimate. Management reaffirmed FY 2026 revenue guidance of $59.5B to $62.5B and adjusted EPS guidance in the $2.80 to $3.00 range — both unchanged from the prior quarter. The implication: Q1 strength was real but Pfizer is not yet willing to take the full year up. For investors running a careful PFE stock price analysis, that conservatism is more reassuring than ambitious guidance would have been.
The composition of revenue is more important than the headline. Oncology grew 12% YoY in Q1, anchored by Padcev and the Seagen-acquired ADC franchise. Internal Medicine grew 9%, driven by Vyndaqel/Vyndamax (which has held up better than feared on the IRA settlement) and Eliquis. Specialty Care grew 4% but masked an 18% decline in Xeljanz against double-digit growth in newer hospital products. Vaccines declined modestly on Comirnaty seasonality. Crucially, the Covid franchise — Comirnaty plus Paxlovid — generated roughly $1.7B in Q1, a level management increasingly characterises as the new normalised base rather than a continuing source of decline.
PFE Valuation Analysis
PFE is one of the cheapest large-cap pharma stocks on every standard metric. The TTM P/E of 17.5 compresses to roughly 9.4 on FY2026 consensus EPS, well below the 13–15x multiple typical of branded pharma peers. The forward dividend yield is 6.7% — top decile within the S&P 500 — and the payout ratio remains manageable at roughly 80% of adjusted earnings.
| Metric | PFE | Pharma Peer Median | S&P 500 |
|---|---|---|---|
| P/E (TTM) | 17.5 | 22 | 24 |
| Forward P/E | 9.4 | 14 | 20 |
| EV/EBITDA | 8.2 | 11.5 | 15 |
| Dividend Yield | 6.7% | 2.9% | 1.32% |
| FCF Yield | 8.1% | 4.5% | 3.0% |
The valuation discount is not a mystery: investors are pricing in patent cliffs on Eliquis (loss of exclusivity in 2028), Ibrance (2027), and Xeljanz (already deteriorating), and they are not yet willing to credit the obesity pipeline with material 2028+ revenue. A discounted cash flow that assumes Metsera’s lead asset reaches $4B peak sales by 2032 generates a fair value near $34. The same DCF without obesity contribution lands closer to $24. The current $26.58 price is, in effect, the market assigning a low double-digit probability of obesity success.
Bullish and Bearish Analyst Opinions on Pfizer
The bullish and bearish analyst opinions on Pfizer split along time horizon. Bulls underwrite the 2028+ obesity readouts and treat today’s price as a compelling entry. Bears focus on the next 24 months of patent cliffs and a Covid revenue base that has not fully stabilised. The 35-analyst median price target of $27.00 sits between those two views; the 14-analyst Buy-rating consensus of $29.29 leans modestly bullish.
| Bull Side | Bear Side |
|---|---|
| Q1 2026 adjusted EPS of $0.75 beat consensus; revenue +5% YoY | Eliquis loss of exclusivity in 2028 is a $7B+ revenue cliff |
| $10B Metsera acquisition gives PFE 10 Phase III obesity studies in flight | Goldman Sachs (Hold, $26): obesity pipeline won’t contribute meaningful revenue before 2028 |
| 6.7% dividend yield with 80% payout ratio still supports the cash return | Ibrance and Xeljanz erosion accelerating; CDK4/6 class becoming generic |
| Reaffirmed 2026 revenue guidance of $59.5–62.5B through tariff uncertainty | P/E of 17.5 already reflects modest pipeline recovery |
| Median analyst target of $27, average $29.29 with high of $35.46 | Covid franchise still ~10% of revenue with declining vaccination uptake |
The most useful frame is to separate the 12-month thesis from the 36-month thesis. Over the next 12 months, PFE is a yield-and-pipeline-optionality story — investors are paid 6.7% to wait for the next leg of obesity Phase III readouts. Over 36 months, the stock either rerates higher on a credible obesity launch trajectory or compresses lower as Eliquis erosion outpaces pipeline contribution. The 14-analyst consensus is comfortable owning the name through that uncertainty.
PFE Stock Forecast 2026: Analyst Price Targets
The PFE stock forecast 2026 picture is one of the most consensus-driven in large-cap pharma. Of 35 analysts publishing price targets, the median is $27.00, the average is $29.29, the high is $35.46, and the low is $25.00. Goldman Sachs sits at $26 with a Hold. Cantor Fitzgerald and Wells Fargo both anchor the bull side near $34.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Cantor Fitzgerald | Louise Chen | Overweight | $35 |
| Wells Fargo | Mohit Bansal | Overweight | $34 |
| Bank of America | Tim Anderson | Buy | $32 |
| Morgan Stanley | Terence Flynn | Equal Weight | $28 |
| Goldman Sachs | Asad Haider | Hold | $26 |
| Leerink | David Risinger | Market Perform | $25 |
Our base case for PFE sits at $30 over a 12-month horizon, slightly above the $29.29 consensus but below the bullish $34–$35 cluster. The bull case at $34 requires Metsera’s lead asset to clear an unambiguous Phase III readout and management to formally guide to obesity contribution in 2027 P&L. The bear case at $24 assumes Eliquis erosion runs faster than the 2028 step-down and obesity pipeline disappoints. The risk/reward favours bulls at current levels — the 6.7% yield and modest forward P/E provide downside support, while pipeline catalysts skew upside.
PFE Pipeline and Patent Cliff Roadmap
The single most contested datapoint in any PFE stock price analysis is the size of the 2028 patent cliff. Eliquis, partnered with Bristol-Myers, generated roughly $7 billion of Pfizer-attributable revenue in 2025 and loses meaningful exclusivity in 2028. Ibrance ($4.5B in 2025) is facing CDK4/6 class genericisation through 2027–2028. Vyndaqel/Vyndamax has held up better than feared on a 2025 IRA settlement that delays generic entry to 2028, but it too steps down materially after that.
The offsets are anchored in three pipeline buckets. First, the obesity portfolio from the Metsera acquisition: 10 Phase III studies will read out across 2026 and 2027, with the lead asset (an ultra-long-acting peptide aimed at monthly maintenance dosing) targeting a 2028 regulatory filing. Second, Pfizer’s emerging oncology pipeline, anchored by the Seagen acquisition’s antibody-drug conjugate platform — three new launches are expected in 2027. Third, recurring vaccine revenue from Comirnaty plus the next-generation RSV combination shot Abrysvo, which has stabilised at roughly $3 billion of annualised revenue.
Run the math at consensus: 2025 revenue of $63.6B steps down to a guidance midpoint of $61B for 2026, then likely to $56–58B for 2028 before pipeline contributions return the company to growth in 2029. The cash flow trough is real but manageable. The dividend safety analysis comes back to whether free cash flow stays above the roughly $9B annual payout requirement during that trough — at current consensus, it does, but with a narrower buffer than Pfizer has had in the last decade.
For investors deciding between Pfizer and other large-cap pharma, the comparison set matters. AbbVie stock price has navigated a similar Humira cliff with Rinvoq and Skyrizi; Pfizer is asking investors to underwrite the same playbook with Metsera, Seagen, and a re-energised pipeline. The risk-reward favours bulls if you believe management can execute the bridge — and is unfavourable if you think the obesity launches slip beyond 2028.
How to Trade PFE via MEXC
MEXC offers Pfizer as a tokenized US stock pair. The PFE USDT exchange lets global users get exposure to Pfizer 24/7 without opening a US brokerage account, with the token settled in USDT and quoted against the underlying NYSE price during regular trading hours.
For income-oriented investors, the tokenized version functions primarily as a directional trade rather than a yield vehicle — verify whether the specific MEXC token participates in PFE’s quarterly dividend distributions before sizing a position based on yield. As a trading instrument, the lower beta of PFE (roughly 0.6 versus the S&P 500) means typical daily moves are 0.5–1.5% with outsized moves clustered around earnings dates and pipeline announcements.
PFE Stock Forecast FAQs
Is PFE a good stock to buy in 2026?
For income and value investors, the case is solid: 6.7% dividend yield, 9.4x forward P/E, and a 14-analyst average target of $29.29. For growth investors, PFE is a wait — the obesity catalysts that would justify a meaningful rerate are 2027 events at the earliest. The honest answer is that PFE is a Buy for the right investor profile rather than a universal one.
What is the PFE stock price prediction for 2026?
The 14-analyst Buy-rating consensus 12-month target is $29.29; the broader 35-analyst median is $27.00, with a range of $25 to $35.46. Our base case is $30. The wide gap between mean and high reflects how much of the upside is tied to obesity pipeline outcomes that remain uncertain.
What are the bullish and bearish analyst opinions on Pfizer?
Bulls (Cantor, Wells Fargo, BofA) point to the $10B Metsera acquisition, 10 Phase III obesity studies in flight, and a 6.7% dividend yield supported by 80% payout coverage. Bears (Goldman Sachs, Leerink) point to Eliquis patent expiry in 2028, Ibrance erosion, and the gap between today’s earnings power and a credible obesity revenue ramp. Both sides agree the dividend is safe — they disagree on whether the stock can rerate before the patent cliffs hit.
What is Pfizer’s dividend yield and is it safe?
Pfizer’s forward dividend yield is 6.7%, one of the highest in the S&P 500. The payout ratio is roughly 80% of adjusted earnings and Q1 free cash flow comfortably covers the current run-rate. Coverage tightens through 2028 as Eliquis loses exclusivity, but management has explicitly committed to defending the dividend, and the Metsera acquisition was structured to avoid forcing a payout cut.
What is Pfizer’s Metsera acquisition?
Pfizer acquired Metsera in November 2025 for $65.60 per share in cash plus a contingent value right of up to $20.65 per share — a deal that values the obesity-focused biotech at roughly $10 billion including the CVR. Metsera brings a portfolio of ultra-long-acting peptides aimed at monthly-maintenance obesity dosing. Pfizer plans to advance 10 Phase III studies in 2026 with a first regulatory approval targeted for 2028.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.
